-
-
-
-
-
-
-
Ultragenyx reports preliminary 2025 revenue of $672-674 million
-
-
-
-
-
-
-
Ultragenyx Pharma (RARE) PT Raised to $136 at Canaccord Genuity
-
-
-
-
-
-
-
Key Biotech Events to Watch, Week of 5/15/2023
-
-
-
-
-
-
-
Ultragenyx and Kyowa Kirin Announce FDA Acceptance and Priority Review Designation of Supplemental Biologics License Application for Crysvita® (burosumab) for Tumor-Induced Osteomalacia (TIO)
-
-
-
-
-
-
-
Ultragenyx Reports Third Quarter 2019 Financial Results and Corporate Update
-
-
-
-
-
-
-
Kyowa Kirin and Ultragenyx Announce Crysvita® (burosumab) Receives Conditional Marketing Authorisation in Europe for the Treatment of X-Linked Hypophosphatemia in Children
-
-
-
-
-
-
-
Ultragenyx Pharma (RARE) PT Lowered to $51 at Bernstein
-
14,982 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

